Cargando…

E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial

BACKGROUND: People with mental illness have higher rates of smoking than the general population and are at greater risk of smoking-related death and disability. In smokers from the general population, electronic cigarettes (e-cigarettes) have been shown to have a similar effect on quit rates as nico...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Brien, Brigid, Knight-West, Oliver, Walker, Natalie, Parag, Varsha, Bullen, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374189/
https://www.ncbi.nlm.nih.gov/pubmed/25814920
http://dx.doi.org/10.1186/s12971-015-0030-2
_version_ 1782363441833443328
author O’Brien, Brigid
Knight-West, Oliver
Walker, Natalie
Parag, Varsha
Bullen, Christopher
author_facet O’Brien, Brigid
Knight-West, Oliver
Walker, Natalie
Parag, Varsha
Bullen, Christopher
author_sort O’Brien, Brigid
collection PubMed
description BACKGROUND: People with mental illness have higher rates of smoking than the general population and are at greater risk of smoking-related death and disability. In smokers from the general population, electronic cigarettes (e-cigarettes) have been shown to have a similar effect on quit rates as nicotine replacement therapy, but little is known about their effect in smokers with mental illness. METHODS: Secondary analysis of data from the ASCEND trial involving 657 dependent adult smokers motivated to quit, randomised to 16 mg nicotine e-cigarette, 21 mg nicotine patch, or 0 mg nicotine e-cigarette, with minimal behavioural support. Using self-reported medication use and the Anatomical Therapeutic Chemical Classification System, we identified 86 participants with mental illness and analysed their cessation and smoking reduction outcomes. RESULTS: For e-cigarettes alone, and all interventions pooled, there was no statistically significant difference in biochemically verified quit rates at six months between participants with and without mental illness, nor in smoking reduction, adverse events, treatment compliance, or acceptability. Rates of relapse to smoking were higher in participants with mental illness. Among this group, differences between treatments were not statistically significant for cessation (patch 14% [5/35], 16 mg e-cigarette 5% [2/39], 0 mg e-cigarette 0% [0/12], p = 0.245), adverse events or relapse rates. However, e-cigarette users had higher levels of smoking reduction, treatment compliance, and acceptability. CONCLUSIONS: The use of e-cigarettes for quitting appears to be equally effective, safe, and acceptable for people with and without mental illness. For people with mental illness, e-cigarettes may be as effective and safe as patches, yet more acceptable, and associated with greater smoking reduction. TRIAL REGISTRATION: Australian New Zealand Clinical trials Registry, number: ACTRN12610000866000.
format Online
Article
Text
id pubmed-4374189
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43741892015-03-27 E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial O’Brien, Brigid Knight-West, Oliver Walker, Natalie Parag, Varsha Bullen, Christopher Tob Induc Dis Research BACKGROUND: People with mental illness have higher rates of smoking than the general population and are at greater risk of smoking-related death and disability. In smokers from the general population, electronic cigarettes (e-cigarettes) have been shown to have a similar effect on quit rates as nicotine replacement therapy, but little is known about their effect in smokers with mental illness. METHODS: Secondary analysis of data from the ASCEND trial involving 657 dependent adult smokers motivated to quit, randomised to 16 mg nicotine e-cigarette, 21 mg nicotine patch, or 0 mg nicotine e-cigarette, with minimal behavioural support. Using self-reported medication use and the Anatomical Therapeutic Chemical Classification System, we identified 86 participants with mental illness and analysed their cessation and smoking reduction outcomes. RESULTS: For e-cigarettes alone, and all interventions pooled, there was no statistically significant difference in biochemically verified quit rates at six months between participants with and without mental illness, nor in smoking reduction, adverse events, treatment compliance, or acceptability. Rates of relapse to smoking were higher in participants with mental illness. Among this group, differences between treatments were not statistically significant for cessation (patch 14% [5/35], 16 mg e-cigarette 5% [2/39], 0 mg e-cigarette 0% [0/12], p = 0.245), adverse events or relapse rates. However, e-cigarette users had higher levels of smoking reduction, treatment compliance, and acceptability. CONCLUSIONS: The use of e-cigarettes for quitting appears to be equally effective, safe, and acceptable for people with and without mental illness. For people with mental illness, e-cigarettes may be as effective and safe as patches, yet more acceptable, and associated with greater smoking reduction. TRIAL REGISTRATION: Australian New Zealand Clinical trials Registry, number: ACTRN12610000866000. BioMed Central 2015-03-24 /pmc/articles/PMC4374189/ /pubmed/25814920 http://dx.doi.org/10.1186/s12971-015-0030-2 Text en © O'Brien et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
O’Brien, Brigid
Knight-West, Oliver
Walker, Natalie
Parag, Varsha
Bullen, Christopher
E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial
title E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial
title_full E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial
title_fullStr E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial
title_full_unstemmed E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial
title_short E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial
title_sort e-cigarettes versus nrt for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ascend trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374189/
https://www.ncbi.nlm.nih.gov/pubmed/25814920
http://dx.doi.org/10.1186/s12971-015-0030-2
work_keys_str_mv AT obrienbrigid ecigarettesversusnrtforsmokingreductionorcessationinpeoplewithmentalillnesssecondaryanalysisofdatafromtheascendtrial
AT knightwestoliver ecigarettesversusnrtforsmokingreductionorcessationinpeoplewithmentalillnesssecondaryanalysisofdatafromtheascendtrial
AT walkernatalie ecigarettesversusnrtforsmokingreductionorcessationinpeoplewithmentalillnesssecondaryanalysisofdatafromtheascendtrial
AT paragvarsha ecigarettesversusnrtforsmokingreductionorcessationinpeoplewithmentalillnesssecondaryanalysisofdatafromtheascendtrial
AT bullenchristopher ecigarettesversusnrtforsmokingreductionorcessationinpeoplewithmentalillnesssecondaryanalysisofdatafromtheascendtrial